CTOs on the Move

Mpathy Medical

www.mpathymedical.com

 
Mpathy Medical is a Raynham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

A.R.E.B.A. Casriel

A.R.E.B.A. Casriel is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CRS Medical Technologies

CRS Medical Technologies is a New Berlin, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harbour Health Systems

Harbour Health Systems is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

Vyne Medical

Vyne Medical serves a growing base of more than 800 active hospital and healthcare system clients nationwide. Best practices are hardwired through technology solutions proven to help hospitals achieve sustainable top performance. Our solutions create a unified view of patient health data, capturing information at the point of exchange and making it available at the point of need for faster response times, smoother transitions, improved patient experience, and better health outcomes.